A new medication may offer an alternative to statins in managing high cholesterol levels, as revealed by scientists. Recent research has unveiled how heightened cholesterol levels disrupt the liver’s natural defenses and a potential drug that could counteract this effect.
Despite the availability of various treatment options, such as statins, many individuals still struggle to achieve healthy cholesterol levels or encounter difficulties with the side effects of current medications. In the UK, commonly prescribed statins like Atorvastatin (Lipitor) and Simvastatin (Zocor) help regulate cholesterol and reduce the risk of heart disease. However, other alternatives like Fluvastatin, Rosuvastatin, and Pravastatin are also available.
While statins like Atorvastatin (Lipitor) can lead to muscle discomfort in some patients, severe muscle damage is rare, and many individuals experience no side effects. American researchers have recently disclosed a hidden biological mechanism that explains how diets high in cholesterol impede the body’s ability to eliminate harmful LDL cholesterol from the bloodstream. They have identified a safe drug candidate that could potentially address this issue.
The study, published in the journal Nature, utilized a combination of mice and human cells to uncover a previously unknown mechanism that hinders the body’s cholesterol removal process. This mechanism is activated by a protein called Ral in response to high dietary cholesterol levels, resulting in a reduction of LDL receptors that help clear cholesterol from the blood. By inhibiting the enzyme CTSA, researchers were able to stabilize LDL receptors and significantly lower LDL cholesterol levels in mice.
The lead researcher, Professor Alan Saltiel, emphasized the importance of exploring new cholesterol-lowering options, especially for individuals who struggle to reach safe levels with existing medications. He noted that the investigational drug, originally intended for heart failure treatment, has shown promise in early clinical trials and is now poised for further testing in a Phase 2 trial targeting high cholesterol.
The discovery of this novel pathway presents an opportunity for a potential new treatment option for patients dealing with high cholesterol, with hopes of expediting the development process through clinical trials.